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Abstract
Background: Four oral anti-tuberculosis drugs are conceived
to be the most effective ones to eradicate Mycobacterium tubercu-
losis bacteria and to obviate the resistant organisms. However, the
patients’ adherence and medication discrepancies are obstacles to
achieving the goal. This study aimed to define the anti-tuberculo-
sis drugs used in the hospitals and to detect the discrepancies in
the continuity of the tuberculosis treatment. 
Design and Methods: This retrospective cross-sectional study
was based on medical records of adult patients, and was conducted
in two district tertiary care hospitals. Only 35 out of 136 patient
records from Hospital A and 33 out of 85 records from Hospital B
met the inclusion criteria. 
Results: The most common systemic anti-infective drugs in
the study were ceftriaxone (51.80 DDD/100 patient-days) used in
Hospital A and isoniazid (59.53 DDD/100 patient-days) used in
Hospital B. The number of rifampicin prescriptions was less than
that of isoniazid. Each patient received an average of two
DDD/100 patient-days, which is an under dosage for an effective
treatment. 
Conclusion: This study showed a medication discrepancy of
tuberculosis therapy. Tuberculosis patients’ medical histories are
not under the full attention of treating physicians wherever they
are admitted. Thus, medication reconciliation is needed to accom-
plish the goal of a Tuberculosis-free world in 2050. 
Introduction
Tuberculosis is a global disease burden. The target of the
Sustainable Development Goals (SDGs) for tuberculosis (TB) is
to achieve 80% reduction in TB incidence by 2030 with the cur-
rent success of curtailing the global TB incidence barely at 1.5%
annually.1 Thirty-eight percent of the TB global deaths were
observed in the South Asian region.2 The incidence of TB cases
and the rifampicin-resistant (RR) or multidrug-resistant (MDR)
TB has remained stable over time.3 In 2018, Indonesia had 8% of
tuberculosis cases worldwide, the third highest ranked country,
after India (27%) and China (9%). Indonesia had a global warning
because there was a 70% rise in new cases added from 2015-2018,
28% of it in period 2017-2018. In 2018, there was 1.020.000 inci-
dent. The incidence rate was 391 per 100.000 population.
Indonesia’s situation was distressing not only because of new
tuberculosis cases but also there was a 10% gap between the num-
ber of new cases reported and the estimated incident cases, due to
under-reporting of detected cases or under-diagnosis. Sometimes
under-diagnosis occurs because of failure to test for TB or diag-
nostic tests that are not sufficiently sensitive or specific to ensure
accurate identification of tuberculosis cases when people go to
health facilities.4 This situation arises not only because of the non-
specific TB signs and symptoms that were undiagnosed,5
delayed,6 or transmitted, but also because of unfinished,7-9
unrecorded, and abruptly abandoned treatments. All these may
occur when the patients are seeking the care of other healthcare
facilities.4 Based on the patient pathway analysis (PPA) studies in
13 countries, less than 50% of the TB patients were permanently
cured; the remainder had a possibility to relapse.1 The PPA
methodology was developed to better understand the alignment
between care-seeking patients and TB service availability.
Indonesia Ministry of Health targeted tuberculosis (TB) elimina-
tion by 2035 and TB free by the year 2050. To achieve it, the reg-
ulation stated that the Central Government, Local Government,
and the community are responsible for organizing TB control.10
Besides public hospitals and health centers (puskesmas), there are
a lot of private hospitals and private medical practices. The gov-
ernment supports the government’s health facilities financially;
whereas the private hospital’s income is from the patients’ out-of-
pocket (OOP) payments.11,12 Among TB patients, in 2015, notified
Significance for public health
Among other infectious diseases, tuberculosis causes not only more death in all countries and age groups, but also threatens global health with multidrug-
resistant TB. Tuberculosis is curable but may have uncertain diagnosis and needs continuation treatment for a minimum of six months. Recently, there is some
investigation of the patient pathway for tuberculosis care-seeking; this study showed that even though the patient goes to public health services, discontinua-
tion of therapy happens. The unfulfilled medication needs of tuberculosis patients, should increase awareness about TB resistance hazards and encourage
healthcare professionals, healthcare management, and government, particularly in Indonesia, to increase microbiology capacity and develop an information
system to connect patient data in the primary care and secondary care.
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cases were primarily being treated in the public sector, which
accounts for 91% of notified cases, whereas the private sector only
notified 9% of cases. The low notification rate in the private sector
leads to an underestimation of TB treatment in private facilities. A
PPA aimed to identify the patient care-seeking direction and the
availability of TB diagnostic and treatment services; to estimate
the missing tuberculosis cases.13 General practitioners and medical
specialists who work at the government’s health facilities had bet-
ter knowledge of TB control regulation program and management
than who work in the private sector.14,15 The levels of the public
health system are classified into several types. These types are
rural health care centers (primary care), district hospitals (sec-
ondary care), and referral hospitals (tertiary care). The PPA cover-
age in each of the levels of the public health system includes the
availability of the TB screenings, diagnoses, and treatments at var-
ious levels to minimize delays in the experiences of care-seeking
or treatment initiations, inappropriate care access, or missed fol-
low-ups during one or more phases of medication.16-18
There is a drug-related problem related to the transfer of
patients within primary, secondary and tertiary care. One of the
most common problems within health care institutions is that TB
patients often miss follow-ups or skip treatments. These missed
follow-ups may impede the successful treatments (the patients’
total recovery process from the disease), particularly if the reason
for the patient’s admittance to the hospital is not triggered by res-
piratory illness.19,20
The harmonization of the drug treatment is challenging when
the data are not synchronized at all levels of care institutions and
units.21 Medication reconciliation is the process of identifying the
most accurate list of a patient’s current medicines, including their
names, the dosage, the frequencies and the routes of administra-
tion; any medication discrepancies will increase medication error
risk.22 Thus, a complete list of medications that is accurately com-
municated particularly to TB patients is needed.23 Accordingly,
this study is aimed to define the anti-tuberculosis drug use for inpa-
tients and to detect the drug use gap in the rural health care centers
(primary care) and district hospitals (secondary care).
Design and methods
This research was an observational descriptive study with a
cross-sectional design and a retrospective approach. This research
material was drawn from medical record data of adult patients (17-
65 years old) with diagnosis of pulmonary tuberculosis and hospi-
talized with the ICD-X code A15.0 (verified using sputum
microscopy with or without culture), integrated patient care
records, nurse/midwife observation records, and drug administra-
tion forms. Primary healthcare refers (the patient’s tuberculosis) to
the hospital for secondary care. Patient’s data in two referral public
hospitals, type B classification, in East Java province, were collect-
ed and analyzed. The distance between these two hospitals
(Surabaya city and Pasuruan district) was 67 km. Data collection
was performed in adult patients with pulmonary tuberculosis that
were hospitalized from January through December 2018. These
two hospitals were tertiary care hospitals with a total of 223 and
323 inpatient beds respectively.
In this study, antibiotic use profiles were defined as the number
of anti-tuberculosis drug (OAT) administered to inpatients in one
year expressed in DDD/100 patient-days units.24 The calculation
was expressed using the DDD (Defined Daily Dose) method where
each antibiotic had DDD values determined by WHO based on its
average and main indications in adults.25
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Table 1. Baseline characteristics of the patients.
Characteristics                                                                                                  Hospital A (N=35)                            Hospital B (N=33)
Gender                                                                            Male                                                                        20 (57.1%)                                                         17 (51.5%)
                                                                                         Female                                                                    15 (42.9%)                                                         16 (48.5%)
Age                                                                                   17-25                                                                          2 (5.7%)                                                             3 (7.5%)
                                                                                         25-35                                                                          1 (2.9%)                                                            5 (12.5%)
                                                                                         35-45                                                                         7 (20.0%)                                                           5 (12.5%)
                                                                                         45-55                                                                        13 (37.1%)                                                         11 (27.5%)
                                                                                         55-65                                                                        12 (34.3%)                                                          9 (22.5%)
Payments                                                                        Health insurance                                                  33 (94.3%)                                                         22 (66.7%)
                                                                                         Out-of-pocket                                                         2 (5.7%)                                                           11 (33.3%)
Length of stays (days)                                                Mean                                                                              6.3                                                                        6.8
                                                                                         SD                                                                                   2.0                                                                        3.6
                                                                                         Range (min-max)                                                     3 – 13                                                                 2 – 19
                                                                                         Total                                                                               222                                                                       223
Total days of antibiotic therapy                                                                                                                         194                                                                        –
Total days of anti- tuberculosis therapy                                                                                                          108                                                                       154
Weight (kg)                                                                   <50 kg                                                                      8 (22.9%)                                                          23 (69.7%)
                                                                                         50-70 kg                                                                   25 (71.4%)                                                         10 (30.3%)
                                                                                         Not Available                                                           2 (5.7%)                                                               0 (0%)
Patient’s tuberculosis category                                Category 1, intensive phase                               22 (62.9%)                                                         18 (54.5%)
                                                                                         Category 1, continuation phase                         4 (11.4%)                                                            1 (3.0 %)
                                                                                         Relapse                                                                   7 (20.0%)                                                          14 (42.5%)
                                                                                         Not Available                                                           2 (5.7%)                                                               0 (0%)
Diagnostic test                                                              Rapid molecular diagnostic                               20 (57.1%)                                                         21 (63.6%)
                                                                                         Ziehl–Neelsen staining                                      13 (37.1%)                                                           2 (6.0%)
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The DDD/100 patient-days was calculated for all the patients
receiving antibiotic therapies using the following equation:
The start and stop date of oral anti-tuberculosis drug use was
collected from the patient’s medical record to calculate days of
therapy, whereas the date of admission and date of discharge to cal-
culate the length of stay. Delays in oral anti-tuberculosis (OAT)
treatment were noted if the date of admission preceding the date of
start OAT use.
Results
Baseline characteristics in both hospitals were similar except
in the patient weight and categories of the TB (Table 1). The num-
ber of patients weighing 50-70 kg in Hospital A (71.4%) was more
than that in Hospital B (30.3%). The category of relapse in
Hospital A (20.0%) was less than that in Hospital B (42.5%). There
were 206 available medical records of pulmonary tuberculosis
patients. Only 68 of 206 records (33.0%) met the inclusion criteria.
Patients excluded were twenty-three patients (11.2%) aged ≤17
years old, 54 patients (26.2%) aged >65 years old, 41 patients
(19.9%) with other infectious diseases besides TB, and 20 patients
(9.7%) with incomplete data. Most patients are male, aged 45-55
years old, with hospitalization paid using health insurance, catego-
ry 1 TB (Table 1). Among all rapid molecular diagnostic test
(41/68, 60%), only one of them was rifampicin-resistant.
Anti-tuberculosis drug dosage was defined by considering the
patient’s weight.10,26 This study shows the differences between the
prescribed dosage and the WHO standard. The hospital prescribed
dosage was lower than that the WHO standard dosage (Table 2). In
Hospital A there were four patients (weighing 51 kg, 60 kg, 67kg,
and 70 kg) who received 600 mg of rifampicin. For patients whose
weight is 51kg, for the first consecutive five days, they were pre-
scribed with the 600mg of rifampicin, and for the next consecutive
two days they were prescribed with 450mg. In Hospital B, there
were different care- or treatment-related factors where patients
received 750 mg of ethambutol, had a history of TB treatment for
one month, or continued with the hospital’s previous treatment on
the first day of admission. However, after TB Rapid Molecular
Diagnostic test results were positive and rifampicin-resistant, the
treatment with rifampicin was stopped.
In Hospital A, 11 antibiotics were prescribed and the number
of anti-TB drug was 108.8 DDD/100 patient-days (52.6%), where-
as in Hospital B, only four antibiotics were administered and all of
them were anti-TB drugs with 196.28 DDD/100 patient-days
(Table 3). The average of antibiotic days of therapy is shorter than
the average of the patient’s length of stays (Table 1, Table 3). This
                            Article
Hospital A
Name                               ATC code        DDD/100 patient days (%)
Ceftriaxone (P)                          J01DD04                               51.80 (25.0)
Isoniazid (O)                               J04AC01                               48.05 (23.2)
Rifampicin (O)                           J04AB02                              32.66 (15.8)
Levofloxacin (P)                        J01MA12                              32.43 (15.7)
Ethambutol (O)                          J04AK02                               26.05 (12.6)
Ofloxacin (O)                             J01MA01                                 8.11 (3.9)
Cefotaxime (P)                          J01DD01                                 2.36 (1.1)
Amoxicillin (O)                           J01CA04                                 2.10 (1.0)
Pyrazinamid (O)                         J04AK01                                 2.04 (1.0)
Azithromycin (O)                       J01FA10                                 0.75 (0.4)
Cefixime (O)                              J01DD08                                0.68 (0.3)
Total                                                                                            207.03 (100)
Hospital B
Name                               ATC code        DDD/100 patient days (%)
Isoniazid (O)                               J04AC01                               59.53 (30.6)
Rifampicin (O)                           J04AB02                               46.91 (24.1)
Pyrazinamide(O)                        J04AK01                               44.08 (22.7)
Ethambutol (O)                          J04AK02                               42.63 (21.9)
Streptomycin (P)                       J01GA01                                 3.14 (2.0)
                                                                                                                
                                                                                                                
                                                                                                                
                                                                                                                
                                                                                                                
                                                                                                                
Total                                                                                            196.28 (100)
Table 3. Drugs used at hospitals A and B.
Table 2. Discrepancies in dosage.
Name                      ATC code              WHO-based DDD                    Prescription       Days of therapy
                                                                                                                                                                  Hospital A                       Hospital B
Isoniazid (O)                   J04AC01                                0.3 gram                                          1x 0.3 gr                                                      3.2                                              4.42
                                                                                                                                                     1x 0.4 gr                                                      3.5                                                 -
Rifampicin (O)                J04AB02                                0.6 gram                                           1x 0.3gr                                                      4.5                                                 -
                                                                                                                                                    1x 0.45 gr                                                     2.9                                              4.42
                                                                                                                                                     1x 0.6 gr                                                      2.8                                                 -
Pyrazinamide (O)           J04AK01                                1.5 gram                                            1x 1 gr                                                       2.0                                              4.15
Ethambutol (O)              J04AK02                                1.2 gram                                           1x 0.5gr                                                      1.0                                                 -
                                                                                                                                                    1x 0.75 gr                                                     2.0                                              4.07
                                                                                                                                                       1x 1 gr                                                       3.8                                              5.00










drug-related problem will threaten the success of TB treatment.27
Most patients in the hospitals were delayed in receiving the
anti-TB drugs since these patients needed to wait for the laboratory
test results (Figure 1). Other TB patients had delayed treatments
since they need to be hospitalized first for their cardiac problems.
Two patients in hospital A needed to quit anti-TB treatment due to
adverse drug events.
Discussion
Older adults (aged ≥65 years) with tuberculosis were excluded
from this study because they have unusual clinical manifestations,
delayed diagnoses, and higher rates of adverse drug reactions and
unfavorable outcomes, i.e., hepatitis and gastrointestinal discom-
fort.28,29 Furthermore, older adults with physiological changes and
co-morbidities need dosage adjustment according to weight, renal
function, liver function, and other potentially complicating factors.
These conditions will underestimate the defined daily dose per 100
patient-days value.
Fixed-dose combinations (FDCs) of drugs for TB treatment
have been advocated internationally to prevent the emergence of
drug resistance attributable to inappropriate drug intake or inap-
propriate drug choice problems.30,31 Use of the FDCs can reduce
the risk of an incorrect dosage, simplify drug procurement, and aid
in ensuring adherence without changing the drug dosage.32 An
adult with weight <50kgs needs three tablets of 4 fixed-dose com-
binations (rifampicin 150 mg, isoniazid 75 mg, pyrazinamide 400
mg, ethambutol 275 mg); and four tablets of 4 fixed-dose combi-
nation if their weight >50kgs. The DDD WHO for rifampicin, iso-
niazid, pyrazinamide, ethambutol is 0.6g, 0.3g, 1.5g, 1.2g, respec-
tively;26 therefore every patient had to have 3.0-3.9 DDD per day.
The oral antituberculosis drug dosage was calculated based on
mg/kg body weight and the number of fixed dosed combination
(FDC) tablets. Three tablets of FDC equal to 450 mg rifampicin,
225 mg isoniazid, 1200 mg pyrazinamide, 825 mg ethambutol.
Isoniazid and pyrazinamide are two OAT that are associated with
hepatotoxicity.33 Its severity was dose-dependent. Ethambutol was
known as a bacteriostatic OAT, not bactericidal. Therefore, the pre-
scribed dose for isoniazid, pyrazinamide, and ethambutol, was less
than the standard dose. The change in antimicrobial usage is meas-
ured to evaluate antibiotic stewardship programs outcome.34 The
DDDs per 100 patient-days and days of therapy per patient-days
were the most frequent metrics used to compare antibiotic con-
sumption.35
Twenty percent of the patients encountered diagnostic capacity
at the location where they first sought care based on the results of
Patient Pathway Analysis (PPA). Most initial care tests occur in the
private sector, and case notification lags behind diagnostic confir-
mation in the public sector.13 These so-called missing cases fall
into three groups of patients, i.e. i) some patients never access care
because of financial, geographic, or other barriers; ii) some
patients seek care in the private (or non-state) sectors and are diag-
nosed and treated there, but are not reported to the National
Tuberculosis Control Program (NTP); and iii) some patients were
diagnosed and treated in the public sectors but are not reported to
the NTP. Finding these “missing” patients is essential if the ulti-
mate goal is to end TB. Patient-centered care is a core principle of
the WHO End TB Strategy.1
Medication reconciliation can mitigate discrepancies in patient
care; however, it should be accompanied with effective implemen-
tation strategies.21 Medication discrepancies happen due to an
addition or withdrawal of a drug, a change to the dose or dosage,
                                                                                                    Article
Figure 1. Patient medication profile.
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or an unintended error in prescribing admission medications.36
Understanding a patient’s journey from the emergence of the first
symptoms to presentation and effective treatments is essential. For
most patients, the journey can:
“involve a family member having TB, multiple presentations
to health professionals, previous courses of antibiotic treatments or
truncated courses of TB treatment, non-adherence or defaulting
from treatment, premature discharge from a health facility and
relapse with a more severe form of TB.”37
Understanding the timeline and journey can help health profes-
sionals assess risk at the time of discharge planning, and under-
stand families’ experiences of using health services. Risk assess-
ment is required at specific milestones (every 6 months) in the
treatment.38 The risks are different in admission, in acute and
chronic stages, and during discharge planning. One of the early
risks may involve acute medical and nutritional complications,
such as nosocomial infections. Chronic phase risks include the
potential for non-adherence if discharged too early, or risks of
chronic adverse health and developmental outcomes. Transition
from hospital to outpatient clinics and community health centers
requires that hospital services be intact;38,39 accordingly, good
communication is essential to ensure the intact services.40,41 A sys-
tematic review reported that there is no issue of the gender equity
for access to TB services quantitatively, but some barriers (finan-
cial, physical, stigma, health literacy, delay) are greater among
women than men.42 If the ultimate goal of controlling an infectious
disease is to interrupt transmission, the current global tuberculosis
strategy has not yet succeeded.43
TB diagnosis has entered an era of molecular detection that
provides faster and more cost-effective methods to diagnose and
confirm drug resistance in TB cases whereas diagnosis using con-
ventional culture systems requires several weeks to get the result.
New advances in TB molecular detection, for example, faster and
simpler nucleic acid amplification test (NAAT) and whole-genome
sequencing (WGS), have resulted in shorter times for diagnosis
and, thus, faster TB treatments.44 Fundamental measures of TB
control include early detection and timely treatment of the affected
patient. 
Tuberculosis control depends on early diagnosis and treatment
at the primary health care level. However, many patients get a late
TB diagnosis at hospitals. The delay in time between admission,
diagnosis, treatment, and isolation20 related to patients and health
system factors.45 Patient’s delays are associated with knowledge,
belief, and socio-economic factors. Health system factors are asso-
ciated with negative sputum smear, age (older than 47 years old),
and specialist consultation.20,39 A long delay in the diagnosis of
pulmonary tuberculosis was also reported in Indonesia.46 Adequate
training of healthcare workers in diagnosing and notifying TB, and
improvement in health care services may help to reduce the long
healthcare delays.45-50
Conclusion
This study showed that the delay of medication and potential
stopping of tuberculosis treatment could be reduced by medication
reconciliation when the patient is transferred from a primary care
to a secondary care facility or vice versa. The patients were seeking
cure from TB and long-term tuberculosis treatment made it possi-
ble for these patients to completely miss treatments when they are
being admitted or transferred to another healthcare institution.
Thus, medication reconciliation or harmonization is an essential
and urgent need to eradicate Mycobacterium tuberculosis and avert
its resistance.
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